KIR Alloreactivity, Genotype in Unrelated Donor Selection Not Significant to Pediatric AML, ALL Outcomes
Unrelated donor selection should not be based on KIR in any of the evaluated settings, study results suggest.
Acute Myeloid Leukemia
Features, Outcomes in Therapy-Related vs De Novo Acute Myeloid Leukemia
Clinicopathologic and genetic characteristics of therapy-related and de novo core-binding factor AML were studied in a multicenter, retrospective analysis.
FLAG+/-Ida Linked to Better Outcomes in Non-Favorable–Risk AML
Induction regimen FLAG+/-Ida appears to be more effective than 7+3 in patients with non-favorable risk AML, but prospective data are needed.
Risk Score Developed to Help ID Heart Failure Risk in Leukemia
Risk score identifies risk among patients with acute leukemia treated with anthracyclines before chemo
Evidence Supports Outpatient Management of Some Children With AML Undergoing Intensive Chemotherapy
Although prolonged periods of neutropenia are common following induction and intensification of chemotherapy, this study showed that pediatric patients with AML can be safely managed in the outpatient setting after resolution of neutropenia.
Postremission Oral Azacitidine Maintenance Therapy Proposed As a New Standard of Care in Some Patients With AML
Eligibility criteria for this study included intermediate- or high-risk cytogenetics, and CR or CR with incomplete count recovery following induction chemotherapy.
Caspofungin May Be More Effective Than Fluconazole in Lowering Risk of Invasive Fungal Disease in Young Patients With AML
Although this study was closed early because findings from an unplanned analysis suggested futility, the final analysis did not support that conclusion.
Quality of Life With Busulfan and Fludarabine Compared With Busulfan and Cyclophosphamide
Patients with acute myeloid leukemia and myelodysplastic syndromes reported similar quality of life irrespective of the conditioning regimen the received.
No Influence of Measurable Residual Disease on Haploidentical Transplantation Outcomes in AML
In patients with complete response at transplant, age was found to be the only predictor of clinical outcomes.
Treosulfan May Offer a New Standard for Prehematopoietic Stem Cell Transplantation Conditioning
Patients receiving treosulfan and fludarabine experienced improved event-free and overall survival compared with patients receiving busulfan and fludarabine.
Next post in Hematologic Cancers
